

2022-RA-689-ESGO

FERTILITY-SPARING TREATMENT IN PATIENTS WITH IB1 CERVICAL CANCER – RESULTS OF THE INTERNATIONAL MULTICENTRE RETROSPECTIVE FERTISS STUDY (ENGOT CX14; CEEGOG CX-03)

¹Jiri Slama, ²Ingo Runnebaum, ³Giovanni Scambia, ⁴Martina Aida Angeles, ⁵Kiarash Bahrehmand, ⁶Stefan Kommoss, ³Anna Fagotti, ⁷Fabrice Narducci, ⁸Olga Matylevich, ⁹Jessica Holly, ¹⁰Fabio Martinelli, ¹¹Meriem Koual, ¹²Viacheslav Kopetskiy, ¹³Ahmed El-Balat, ³Giacomo Corrado, ¹⁴Mihai Emil Capilna, ¹⁵Willibald Schroder, ⁵Zoltan Novak, ⁸Alexander Shushkevich, ¹Lenka Fricova, ¹⁶David Cibula. ¹Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; ²Department of Gynecology and Reproductive Medicine, Jena University Hospital, Friedrich Schiller University, Jena, Germany; ³Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart Rome, Rome, Italy; ⁴Claudius Regaud Institute – University Cancer Institute, Toulouse, France; ⁵Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary; ⁶Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany; ⁷Department of Gynecology Oncology, Oscar Lambret Cancer Center, Lille, France; ⁸Gynecologic Oncology Department, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus; ⁹Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; ¹⁰Fondazione IRCCS Istituto Nazionale Tumori – Milan, Milan, Italy; ¹¹Gynecologic and Breast Oncologic Surgery Department, Georges Pompidou European Hospital, Paris, France; ¹²Department of Gynecologic Oncology, National Cancer Institute, Department of Gynecologic Oncology, National Cancer Institute, Kyiv, Ukraine; ¹³Department of Gynecology and Obstetrics, University Clinic Frankfurt, Goethe-University, Spital Uster, Women's Hospital, Uster, Switzerland; ¹⁴First Obstetrics and Gynecology Clinic, 'George Emil Palade' University of Medicine, Pharmacy, Science and Technology Târgu Mureş, Târgu Mureş, Romania; ¹⁵Gynaekologikum Bremen, Bremen, Germany; ¹⁶Department of Gynecology and Obstetrics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

10.1136/ijgc-2022-ESGO.372

Introduction/Background One of the key conditions for selecting candidates for fertility sparing treatment (FST) is a tumour size not exceeding 2 cm in the largest dimension. While there is a consensus on the choice of surgical treatment in stage IA, both radical (radical trachelectomy) and non-radical (simple trachelectomy or conisation) procedures are advocated in stage IB1, often depending on tumor size (>1 cm vs. 1–2 cm) and the presence of LVSI.

Methodology Patients with IB1 cervical cancer were recruited from the international multicenter retrospective FERTISS study. Inclusion criteria were lymph node negativity, age 18–40 years, and any type of FST, regardless of neoadjuvant chemotherapy, histotype, or tumour grade. Parameters representing disease and treatment characteristics were analyzed for risk of recurrence.

Results A total of 356 stage IB1 patients from 44 institutions in 13 countries were enrolled in the study. The mean age of the patients was 31.7 years, 70.2% of them were nulliparous. One-third of the tumours were adenocarcinomas and one-third of cases were LVSI positive. Oncological treatment characteristics are summarized in table 1. During median follow-up of 72 months there were 27 recurrences (7.6%) and 8 deaths (2.3%) from the disease. Recurrence rates did not differ between patients after non-radical cervical procedures (conization or simple trachelectomy) and radical trachelectomy (7.5% vs. 7.7%; $p=0.957$), even after subgroup analysis according to tumour size (<1 cm: 5.2% vs. 7.4%; $p=0.507$; 1–2 cm: 10.9% vs. 8%; $p=0.553$) or presence of LVSI (11.5% vs. 9.4%; $p=0.725$) (table 2).

Abstract 2022-RA-689-ESGO Table 1 Overview of oncological treatment

Stage		IB1 (N=356)
NACT		
No		330 (92.7%)
Yes		26 (7.3%)
Type of LN staging		
Sentinel lymph node biopsy		171 (48.0%)
Pelvic lymphadenectomy		310 (87.1%)
Paraortic lymphadenectomy		15 (4.2%)
Type of cervical procedure		
Non-radical Procedures	Conization	133 (37.4%)
	Simple vaginal trachelectomy	27 (7.6%)
Radical procedures	Laparoscopic radical trachelectomy	30 (8.4%)
	Radical abdominal trachelectomy	93 (26.1%)
	Radical vaginal trachelectomy	67 (18.8%)
	Robotic radical trachelectomy	6 (1.7%)
Repeated cervical procedure		N=65
Hysterectomy		3 (4.6%)
Laparoscopic radical trachelectomy		1 (1.5%)
Radical abdominal trachelectomy		3 (4.6%)
Radical vaginal trachelectomy		4 (6.2%)
Re-conization		37 (56.9%)
Robotic radical trachelectomy		4 (6.2%)
Simple vaginal trachelectomy		13 (20.0%)
Adjuvant chemotherapy		
No		343 (96.3%)
Yes		13 (3.7%)

Abstract 2022-RA-689-ESGO Table 2 Recurrences risk according to different radicality of FST

Category (N; %)	Recurrence				p-value
	Yes		No		
	Less radical	Radical	Less radical	Radical	
IB1	12 (7.5%)	15 (7.7%)	148 (92.5%)	181 (92.3%)	0.957
IB1 L1	6 (11.5%)	5 (9.4%)	46 (88.5%)	48 (90.6%)	0.725
IB L0	4 (4.4%)	8 (6.5%)	86 (95.6%)	115 (93.5%)	0.520
IB1 (<1 cm)	5 (5.2%)	9 (7.4%)	91 (94.8%)	112 (92.6%)	0.507
IB1 (1-2 cm)	7 (10.9%)	6 (8.0%)	57 (89.1%)	69 (92.0%)	0.553

L1 = Lymphovascular space invasion positivity; L0 = Lymphovascular space invasion negativity

Conclusion We have demonstrated that in patients with HPV-associated tumour types, negative regional lymph nodes, and tumour size ≤ 2 cm, oncological outcome after FST is excellent, and it is not inferior after non-radical cervical procedures.

2022-RA-756-ESGO

HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS IN PREGNANCY: CASE SERIES OF 35 PATIENTS

¹Olga P Matylevich, ¹Ilya A Tarasau, ¹Tatsiana U Vertsikhouskaya, ²Sviatlana Y Shelkovich, ¹NN Alexandrov National Cancer Centre of Belarus, Minsk, Belarus; ²Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus

10.1136/ijgc-2022-ESGO.373